A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
Intravenous bolus mitomycin was given at a dose of 10-12 mg/m2 to patients with epithelial ovarian cancer resistant to cisplatin or carboplatin. There were three (12%) partial responses and no complete responses in the 25 patients so treated.